CINECA IRIS Institutional Research Information System

SICCARDI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.113
EU - Europa 3.087
AS - Asia 963
AF - Africa 36
SA - Sud America 12
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 5
Totale 9.225
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.093
DK - Danimarca 1.045
CN - Cina 456
DE - Germania 334
IT - Italia 276
SG - Singapore 252
SE - Svezia 242
IE - Irlanda 240
FR - Francia 181
GB - Regno Unito 174
UA - Ucraina 166
FI - Finlandia 163
KR - Corea 125
AT - Austria 109
PL - Polonia 70
IN - India 35
NL - Olanda 31
VN - Vietnam 29
ZA - Sudafrica 28
CA - Canada 19
BE - Belgio 17
ID - Indonesia 15
EU - Europa 9
TH - Thailandia 8
TW - Taiwan 8
JP - Giappone 7
RU - Federazione Russa 7
UZ - Uzbekistan 7
BR - Brasile 6
IR - Iran 6
ES - Italia 5
CZ - Repubblica Ceca 4
PK - Pakistan 4
PT - Portogallo 4
AU - Australia 3
CH - Svizzera 3
EG - Egitto 3
HK - Hong Kong 3
HR - Croazia 3
NO - Norvegia 3
PH - Filippine 3
AR - Argentina 2
GH - Ghana 2
IL - Israele 2
NZ - Nuova Zelanda 2
PY - Paraguay 2
BD - Bangladesh 1
CO - Colombia 1
CU - Cuba 1
EE - Estonia 1
HU - Ungheria 1
IM - Isola di Man 1
KE - Kenya 1
LI - Liechtenstein 1
MA - Marocco 1
MD - Moldavia 1
ME - Montenegro 1
RO - Romania 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TR - Turchia 1
VE - Venezuela 1
Totale 9.225
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.015
Chandler 424
Beijing 345
Dublin 240
Santa Clara 225
Singapore 206
Fairfield 164
Ashburn 149
Houston 147
Dearborn 143
Villeurbanne 137
Wilmington 126
Jacksonville 125
Princeton 106
Torino 105
Vienna 105
Medford 99
Nyköping 97
Seattle 83
Woodbridge 71
Warsaw 70
Columbus 62
Cambridge 46
Redwood City 46
Fremont 43
New York 38
Boardman 26
Milan 26
Pisa 24
Munich 23
Boston 17
Verona 17
Brussels 16
Guangzhou 16
Toronto 15
Dong Ket 14
Jakarta 14
Falls Church 13
Kunming 11
Amsterdam 10
Hefei 10
Helsinki 10
Nürnberg 10
Cape Town 9
Norwalk 8
Turin 8
Alberton 7
Edinburgh 7
Shanghai 7
Washington 7
Des Moines 6
Isfahan 6
Los Angeles 6
Pune 6
Indianapolis 5
Kharkiv 5
London 5
Rome 5
San Diego 5
Taipei 5
Wuhan 5
Brno 4
Hangzhou 4
Jinan 4
Mountain View 4
Nanjing 4
Phoenix 4
Pretoria 4
Silver Spring 4
Changsha 3
Chengdu 3
Frankfurt am Main 3
Goodwood 3
Hong Kong 3
Leawood 3
Moscow 3
Nanchang 3
Piemonte 3
Redmond 3
Tirupati 3
Zhongxin 3
Accra 2
Asunción 2
Atlanta 2
Bangalore 2
Bangkok 2
Baotou 2
Burlington 2
Copenhagen 2
Costa Mesa 2
Dallas 2
Fuzhou 2
Goiânia 2
Göteborg 2
Hadera 2
Hamburg 2
Leiden 2
Madrid 2
Naples 2
Oslo 2
Totale 5.907
Salva come PNG Salva come JPEG
Nome #
Ceftriaxone bone penetration in patients with septic non-union of the tibia 300
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 289
Raltegravir penetration in seminal plasma of healthy volunteers. 257
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 255
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 244
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 243
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 238
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 233
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 202
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens 183
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 183
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 181
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 178
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 177
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 172
Farmacocinetica dell’anidulafungina in pazienti con fibrosi cistica, trapianto epatico e emodiafiltrazione: dati preliminari. 169
Effect of multidrug-resistant gene polymorphisms on daptomycin concentrations: preliminary results 168
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 167
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 165
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 165
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 163
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 163
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 163
Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia 161
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 159
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters 156
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 156
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 156
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 155
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 155
Influenza dei polimorfismi C3453T, C1236T, G2677T/A del gene MDR1 sulle concentrazioni plasmatiche di daptomicina 154
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 153
Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. 152
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients 148
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 145
Farmacocinetica della caspofungina in pazienti sottoposti a trapianto epatico. 145
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV infected patients 142
Prophylaxis drug monitoring of itraconazole and voriconazole in the paediatric onco-haematological setting 139
Population pharmacokinetics of unboosted atazanavir and influence of the pregnane -x- receptor PXR 63396C > T 138
Is Maraviroc a substrate for SLCO1B1? 136
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 136
Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. 136
ABCB1 3435C>T e CYP2B6 516G>T possono predire le concentrazioni plasmatiche ottimali di Nevirapina 101
Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens. 95
Combined effect of SLCO1B1 521T>C, PXR 63396C>T, and ABCB1 3435C>T on the achievement of therapeutic concentrations of unboosted Atazanavir 92
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. 89
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T predict higher plasma concentrations of nevirapine (NVP). 86
Unexpected drug-drug interaction between tipranavir/ritonavir (TPV/RTV) and enfuvirtide (T20) 81
Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. 81
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir 80
A Population Pharmacokinetic Model Illustrates an Association Between a Pregnane-X-Receptor (PXR) Polymorphism and Boosted Atazanavir Clearance 79
Class-specific relative genetic contribution for key antiretroviral drugs 79
HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. 76
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon 75
Evaluation of 7 different resistence interpretation algoritms and their derived gentotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens 75
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma 72
A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method 71
PXR 63396C>T is a predictor of boosted and unboosted atazanavir plasma concentrations 68
Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV 68
Le concentrazioni plasmatriche di ATV boostato ed unboosted correlano con il polimorfismo 63396C>T del pregnane X receptor. 67
A Simple and Fast Method for Quantification of Ertapenem using Meropenem as Internal Standard in Human Plasma in a Clinical Setting 65
Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient 62
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients 62
PHARMACOKINETICS AND PHARMACOGENETICS OF MARAVIROC IN THE CLINICAL SETTING 59
Plasma concentration of boosted and unboosted Atazanavir are predicted by 63396C>T SNP in the PXR gene 56
Solute Carrier Organic Anion Transporter 1B1 (SLCO1B1) Mediates Transport of Maraviroc Using a X. leavis Model 56
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. 56
PHARMACOKINETICS OF RALTEGRAVIR IN THE CLINICAL SETTING 53
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. 51
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. 45
Intracellular Accumulation of Tipranavir/Ritonavir 40
Impairment in Kidney Tubular Function in Patients Receiving Tenofovir Is Associated with Higher Plasma Tenofovir Levels 39
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. 36
Intracellular Pharmacokinetics of ATV/RTV Is Influenced by Solute Carrier Organic Anion Transporter 3A1 Expression 36
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. 35
Totale 9.666
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.801
article - articoli 0
book - libri 0
conference - conferenze 12.220
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.021
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.483 0 0 0 0 0 393 162 54 76 177 278 343
2020/2021990 265 31 21 55 52 46 60 23 78 80 49 230
2021/20222.229 228 191 227 240 178 191 244 212 139 59 158 162
2022/20231.256 133 50 20 110 152 334 86 98 138 16 83 36
2023/2024467 53 77 28 28 42 82 6 34 5 15 31 66
2024/2025654 8 35 45 96 354 116 0 0 0 0 0 0
Totale 9.666